Non‐alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network?

Summary Psoriasis is an immune‐mediated systemic inflammatory disease that is not limited to the skin but may be associated with arthritis, cardiovascular diseases, metabolic syndrome including diabetes and obesity and, as identified more recently, non‐alcoholic fatty liver disease (NAFLD) that occurs in approximately 50 % of all patients with psoriasis. NAFLD is characterized by accumulation of fat in hepatocytes in the absence of excessive alcohol consumption. Over the last two decades, NAFLD has developed to the most common chronic liver disease with an estimated prevalence of 25 % in the Western population. NAFLD ranges from non‐inflammatory or bland hepatic steatosis to inflammation of hepatic tissue (non‐alcoholic steatohepatitis, NASH) and consecutive liver fibrosis. It is controversial whether the underlying systemic inflammation of psoriasis is contributing to development of NAFLD or if comorbid diseases such as obesity enhance NAFLD development. Recent findings indicate that cytokine‐mediated inflammation through TNFα, interleukin (IL)‐6 and IL‐17 might be the common link between psoriasis and NAFLD. Considering the shared inflammatory pathways, IL‐17 pharmacological blockade, which is already well‐established for psoriasis, may be a promising strategy to treat both psoriasis and NAFLD. Therefore, early detection of NAFLD and a better understanding of its pathophysiology in the context of the systemic inflammation in psoriasis is important with regard to individualized treatment approaches.